Ahmedabad-based Torrent Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in India - Rituximab, Adalimumab and Cetuximab.

Under the terms of the agreement, Reliance Life Science will develop and supply these products to Torrent Pharma for a period of ten years after obtaining all necessary regulatory approvals. The company will manufacture these products at its facility in Navi Mumbai.

Rituximab and Cetuximab cater to the oncology segment and are used in the treatment of various cancers like Leukaemia, Lymphoma, colorectal, head and neck cancers. Adalimumab is the most preferred therapy for the treatment of auto immune disorders like rheumatoid arthritis, psoriasis and IBD.

The licensing agreement with Reliance Life Sciences is expected to significantly boost Torrent Pharma's presence in oncology and dermatology segments in the coming years.